A Clinical Study Comparing the Effectiveness of Virechana and Siravedha Followed by Rohitakadya Churna in Managing Non-Alcoholic Fatty Liver Disease (Yakritodara)

A Comparative Clinical Study To Evaluate The Efficacy Of Virechana And Siravedha Followed By Rohitakadya Churna In The Management Of Yakritodora With Special Reference To Non-Alcoholic Fatty Liver Disease. - ViSiRo-NAFLD Trial (Virechana & Siravedha followed by Rohitakadya Churna in NAFLD)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083637

Enrollment

Registered

2025-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient aged between 18 to 60 years of either sex not taking any medicines for NAFLD will be included in the study. 2. Individual diagnosed as NAFLD case will be included up to grade III (based on radiological finding). 3. Patient fit for Virechana Karma and Siravedha Karma. 4. Patient willing to give informed consent for the study.

Exclusion criteria

Exclusion criteria: 1. Individual suffering from Chronic hepatitis, malignant Jaundice, acute hepatitis (other than infective). 2. Individual with any psychiatric illness. 3. Individual participating in any other clinical trial. 4. Pregnant or lactating females. 5. Alcohol, Smoke and Drug abuser will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Changes in NAFLD scoresTimepoint: 51 days	—

Secondary

Measure	Time frame
Changes in subjective parameters, & USG upper abdomenTimepoint: 66 days	—

Countries

India

Contacts

Public ContactProf Dr Gopesh Mangal

NIA JAIPUR

gmangal108@gmail.com8619849011

Outcome results